IPA Company Profile and Key Details

Short-term trend indicators are bearishly aligned (SMA20 -11.31%, SMA50 8.82%, SMA200 149.75%). The stock’s 14-day RSI is 47.1 (neutral), while the ATR of 0.31 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -36.23% below its high and over 666.67% above its low.

ImmunoPrecise Antibodies Ltd. has 46.15 million shares outstanding. The public float is 41.95 million shares, elevated short interest at 1.59% of float. This equals 725.31 thousand shares. The short ratio is 0.35 days. Institutional investors hold 9.53% of the float. Insiders own 9.07%.

ImmunoPrecise Antibodies Ltd. generated EPS of -$0.67 over the past year. Five-year average earnings growth is -19.06%. The latest quarter delivered EPS of -$0.06. The next quarter is forecast at -$0.04. Next year's EPS is expected at $40.23. ImmunoPrecise Antibodies Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 12, 2026, missed forecasts by 53.92%. The prior quarter beat by 40.01%. Over the last six quarters, Apple has recorded several small beats. These include -7.76% in December 10, 2024.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) shares are up 402.79% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows ImmunoPrecise Antibodies Ltd. trading at a premium to the broader market with a P/E of -7.95. Analyst sentiment is cautious, with the majority of ratings in Speculative Buy territory and a mean price target of $7.50, suggesting 377.71% upside. Our AI forecast model points to short-term weakness (-3.18% over two weeks), a medium-term rise (163.69% over three months), and a longer-term gain (947.77% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ImmunoPrecise Antibodies Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.18%, with price expected at $1.52 by November 04, 2025, within a range of $1.38 to $1.69 3-Month Outlook: Projected rise of 163.69%, reaching $4.14 by January 19, 2026, with a range of $4.10 to $4.17. 1-Year Outlook: Projected gain of 947.77%, with price at $16.45 by October 21, 2026, within a range of $17.12 to $18.11.

ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) closed at $1.62 USD, gaining $0.04 (2.53%) from the previous close of $1.58. The stock is currently mid-range between its 52-week high and low $0.27 and $3.25. With a market capitalization of about $74.77 million, ImmunoPrecise Antibodies Ltd. is classified as a micro-cap and shows lower-than-market volatility (beta ~0.49). Key stats such as the average daily volume over the past year has been around 2.91 million shares, volume is running light vs its 52-week average. Headquartered in Austin, BC, ImmunoPrecise Antibodies Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jennifer Lynne Bath, the company employs approximately 72 people and listed since January 07, 2002. ImmunoPrecise Antibodies Ltd. (IPA) is a global biotechnology firm that, through its subsidiaries, focuses on the development and production of antibodies, alongside offering a broad spectrum of related scientific services.

ImmunoPrecise Antibodies Ltd. trades at a P/E ratio of -7.95, slightly below the S&P 500 average, with a price-to-sales ratio of 5.64 and a price-to-book ratio of 6.98 trading at moderately above to book value. The P/FCF stands at -8.73, also below market averages.